GI Dynamics EndoBarrier found effective against diabetes, obesity

5 October 2011 (Last Updated October 5th, 2011 18:30)

GI Dynamics' EndoBarrier Gastrointestinal Liner has demonstrated blood sugar control and weight loss benefits beyond the implant period in the 12-Month Diabetes and Obesity trial.

GI Dynamics' EndoBarrier Gastrointestinal Liner has demonstrated blood sugar control and weight loss benefits beyond the implant period in the 12-Month Diabetes and Obesity trial.

EndoBarrier is a non-surgical device proven to lower blood glucose levels and promote weight loss in diabetic and obese patients during the implant period.

In the diabetes trial, type II diabetes patients treated with the EndoBarrier for 12 months achieved a mean 2.3% decrease in HbA1c levels, decreased glucose levels from an average of 175.6 at baseline to 137.8 mg/dL and 39% excess weight loss.

It is found that six months after removal of the EndoBarrier, patients experienced only a slight increase in HbA1c levels, from 6.5% to 6.6%.

In the obesity trial, patients reported an average of 46.4% excess weight loss, a mean reduction in HbA1c of 1.4% following 12 months of EndoBarrier treatment.

Six months following the removal of the EndoBarrier, patients maintained as much as 75% of the weight they lost during the treatment period.

The EndoBarrier has received CE mark approval in Europe for implant periods of up to 12 months for treating type 2 diabetes and obesity, and recently received TGA approval in Australia.